CAS 51352-87-5 Nootropic Powder Smart Drug PRL-8-53 Improving Brain Cycle

CAS 51352-87-5 Nootropic Powder Smart Drug PRL-8-53 Improving Brain Cycle

PRL-8-53
Other Names:Methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate hydrochloride
Molecular Formula:C18H22ClNO2
Formula Weight:319.82578
CAS No.:51352-87-5
Appearance:white powder
Purity:99%

PRL-8-53 is a nootropic research compound first synthesized in the 1970’s by Dr Nikolaus Hansl while working at Creighton University. The compound takes its name from creator’s company Pacific Research Labs who were also the (now expired) patent holders. Very little research on this compound is available online. What is available appears to have been conducted by the old patent holder.

The single study involving humans showed PRL-8-53 improved word recollection scores both 24 and 96 hours after initial memorization. Given the low amount of evidence available for this nootropic, we thought it relevant to reference a journal article in which the creator discusses the compound and numerous other human trials it was used in.

Anecdotal reports for this seem favorable, though in the absence of reliable published research and data for prolonged use in humans, it’s not something we can recommend.

Abstract

PRL-8-53 (chemical name Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate) is a synthetic nootropic compound discovered in 1972 and patented in 1975 by the late Dr. Nikolaus Hansl, a neuropharmacologist at Creighton University in Omaha, Nebraska. Preliminary animal tests indicated that the compound was both safe and significantly nootropic, boosting avoidance learning in rodents with no adverse effects. But the real interest in PRL-8-53 was sparked by a 1978 study on human volunteers, which showed that a single dose of the compound could improve word retention scores by more than 200%

Application

PRL-8-53's exact mechanisms of action are not well understood, but it is generally believed to regulate the brain's production of and response to several crucial neurotransmitters. In his reports on human and animal studies Hansl indicated that PRL-8-53 potentiates dopamine, partially restricts production of serotonin, and enhances the brain's response to acetylcholine.

Though Hansl's research report on the 1978 human study suggests those actions, it does not clearly delineate the mechanism of action.The fact that older subjects saw the most nootropic benefit from taking the drug supports the concept that dopamine modulation plays a major role in PLR-8-53's effects. Up-regulating the normal age-related lessening of dopamine production that is associated with cognitive decline could have a significant positive impact on both learning and memory.

Dosage

The only human study on PRL-8-53 was based on the ingestion of a single 5 mg dose. There is no data on the effectiveness or potential toxicity of any other dosage in humans.